Orbital cellulitis as the initial presentation of <scp>L</scp>angerhans cell histiocytosis in an adult patient

Das, Avash; Gupta, Arjun; Naina, Harris V.

doi:10.1002/ajh.24670

Cited by 4 publications

(3 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Literature review in PubMed yielded 68 results using the terms “langerhans cell histiocytosis and orbit” of which there are 15 applicable results outlined below. There were no complications with treatment 1,9–22 …”

Section: Discussionmentioning

confidence: 98%

“…There were no complications with treatment. 1 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 Abbreviations: FNA, fine needle aspiration; ILS, intralesional steroids; IVCT, IV chemotherapy (etoposide, cisplatin), steroids (methylprednisolone or prednisolone); OCT, oral chemotherapy (6 mercaptopurine, vincristine, vinblastine). …”

Section: Discussionmentioning

confidence: 99%

“…There were no complications with treatment. 1 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 …”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Successful treatment of orbital Langerhans cell histiocytosis with stereotactic radiosurgery: A case report and literature review

Etter

Bosse

Wang

et al. 2023

Clinical Case Reports

View full text Add to dashboard Cite

Langerhans cell histiocytosis (LCH) is a rare inflammatory myeloid neoplasm arising from the proliferation of pathologic Langerhans cells. LCH has a spectrum of presentations predominantly affecting male pediatric patients. As LCH is a relatively uncommon diagnosis, there is no standard of care for treatment of the disease and treatment is based largely on clinical judgment, lesion characteristics, and symptoms at presentation. Here we present a case of unifocal, isolated orbital LCH in a 19-year-old young man treated initially with surgical resection. Follow-up imaging 2 months later demonstrated significant regrowth of the mass and no other sites of disease. The recurrent orbital disease was treated with stereotactic radiosurgery (SRS) to 7 Gy in one fraction. Near complete resolution of the mass was achieved with no recurrence after 1.5 years of follow-up. SRS for treatment of orbital LCH is a novel treatment not previously described in the literature which may provide benefit in select cases.

show abstract

Section: Discussionmentioning

confidence: 98%